Cited 0 times in
Angiotensin converting enzyme inhibitors versus angiotensin II type 1 receptor blockers in patients with acute myocardial infarction and prediabetes after successful implantation of newer-generation drug-eluting stents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 홍성진 | - |
dc.contributor.author | 홍성진 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 최동훈 | - |
dc.date.accessioned | 2024-03-22T05:44:08Z | - |
dc.date.available | 2024-03-22T05:44:08Z | - |
dc.date.issued | 2023-08 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198176 | - |
dc.description.abstract | BACKGROUND: Because limited data are available, the present study investigated 2-year major clinical outcomes after angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) therapy in patients with acute myocardial infarction (AMI) and prediabetes after successful implantation of newer-generation drug-eluting stents (DESs). METHODS: Overall, 2932 patients with AMI and prediabetes were classified into two groups - the ACEIs group (n = 2059) and the ARBs group (n = 873). The primary endpoint was the occurrence of patient- -oriented composite outcome (POCO), defined as all-cause death, recurrent myocardial infarction (Re-MI), or any repeat revascularization. The secondary endpoint was definite or probable stent thrombosis (ST). RESULTS: The cumulative incidences of POCO (adjusted hazard ratio [aHR]: 1.020; 95% confidence interval [CI]: 0.740-1.404; p = 0.906), all-cause death (aHR: 1.394; 95% CI: 0.803-2.419; p = 0.238), Re-MI (aHR: 1.210; 95% CI: 0.626-2.340; p = 0.570), any repeat revascularization (aHR: 1.150; 95% CI: 0.713-1.855; p = 0.568), and ST (aHR: 1.736; 95% CI: 0.445-6.766; p = 0.427) were similar between the groups. These results were confirmed after propensity score-adjusted analysis. CONCLUSIONS: In this study, patients with AMI and prediabetes who received ACEIs or ARBs showed comparable clinical outcomes during the 2-year follow-up period. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Via Medica | - |
dc.relation.isPartOf | CARDIOLOGY JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Angiotensin II Type 1 Receptor Blockers / therapeutic use | - |
dc.subject.MESH | Angiotensin Receptor Antagonists / therapeutic use | - |
dc.subject.MESH | Angiotensin-Converting Enzyme Inhibitors / therapeutic use | - |
dc.subject.MESH | Drug-Eluting Stents* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Myocardial Infarction* / complications | - |
dc.subject.MESH | Myocardial Infarction* / diagnosis | - |
dc.subject.MESH | Myocardial Infarction* / therapy | - |
dc.subject.MESH | Percutaneous Coronary Intervention* / adverse effects | - |
dc.subject.MESH | Percutaneous Coronary Intervention* / methods | - |
dc.subject.MESH | Prediabetic State* / complications | - |
dc.subject.MESH | Prediabetic State* / diagnosis | - |
dc.subject.MESH | Prediabetic State* / drug therapy | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Angiotensin converting enzyme inhibitors versus angiotensin II type 1 receptor blockers in patients with acute myocardial infarction and prediabetes after successful implantation of newer-generation drug-eluting stents | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yong Hoon Kim | - |
dc.contributor.googleauthor | Ae-Young Her | - |
dc.contributor.googleauthor | Myung Ho Jeong | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Sung-Jin Hong | - |
dc.contributor.googleauthor | Sang-Ho Park | - |
dc.contributor.googleauthor | Seunghwan Kim | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.identifier.doi | 10.5603/CJ.a2021.0116 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A02269 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04391 | - |
dc.relation.journalcode | J03125 | - |
dc.identifier.eissn | 1897-5593 | - |
dc.identifier.pmid | 34622435 | - |
dc.subject.keyword | angiotensin receptor blocker | - |
dc.subject.keyword | angiotensin-converting enzyme inhibitor | - |
dc.subject.keyword | myocardial infarction | - |
dc.subject.keyword | outcomes | - |
dc.subject.keyword | prediabetes | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 안철민 | - |
dc.contributor.affiliatedAuthor | 장양수 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.citation.volume | 30 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 614 | - |
dc.citation.endPage | 626 | - |
dc.identifier.bibliographicCitation | CARDIOLOGY JOURNAL, Vol.30(4) : 614-626, 2023-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.